Inhaled hormones: Inhaling oxytocin causes autistic people to report feelings of enhanced trust with fictitious partners in a virtual ball game, a study with 13 participants suggests
Participants taking the highest dose of Eli Lillys new GLP-1 drug lost an average of 28.7% of their body weight in a late-stage trial, putting it on track to be a heavyweight in the crowded world of weight-loss and diabetes treatments
Leg weakness and pain (sciatica)
We adjusted for patient age, sex, race, ethnicity, Social Vulnerability Index quintile, starting BMI, weight change after treatment, history of insulin usage, and starting HbA1c
As patients lose weight on GLP-1 therapy, increased mobility often becomes feasible, creating opportunities for enhanced physical activity that further supports weight management and joint function
The Peptide Sciences alternative guide and the research peptide legal framework 2026 guide provide additional context for researchers navigating the current market